Clinical Trials
18 trialsNCT04722172 2026-06-04
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02477696 2026-05-27
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting
NCT05057494 2026-05-19
MAJIC
AstraZeneca
Phase 3 Active not recruiting
NCT02970318 2026-05-11
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT04657094 2026-05-06
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02029443 2026-05-05
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT06205498 2026-04-23
ARISE
AstraZeneca
Active not recruiting
NCT03328273 2026-04-20
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 1 Active not recruiting
NCT03932331 2026-04-20
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
AstraZeneca
Phase 1/2 Active not recruiting
NCT02586857 2026-03-25
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT02717611 2026-03-25
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Acerta Pharma BV
Phase 2 Active not recruiting
NCT04075292 2026-03-05
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca
Phase 3 Active not recruiting
NCT04624633 2026-02-25
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03580928 2026-02-13
AVO
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05971251 2025-10-01
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT02475681 2025-08-27
ElevateTN
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02157324 2025-08-13
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 1 Active not recruiting
NCT03836261 2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3 Active not recruiting